N
Neurogastrx
A specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders
About Neurogastrx
Neurogastrx, Inc. is a privately held biopharmaceutical company focused on developing transformative therapies for gastrointestinal disorders. The company primarily targets conditions like gastroparesis, a severe disorder where the movement of food from the stomach to the small intestine slows or stops, disrupting normal digestion. Neurogastrx's flagship product, NG101, is a novel D2 antagonist designed to minimize the cardiovascular and central nervous system (CNS) side effects commonly associated with this class of treatments. By addressing these safety concerns, NG101 aims to provide a more effective and safer treatment option for gastroparesis patients.
Read full description
The company operates in the biopharmaceutical market, serving patients suffering from gastrointestinal disorders, a segment that is often poorly treated by existing therapies. Neurogastrx's business model revolves around the research, development, and commercialization of its innovative therapies. Revenue is generated through the sale of its proprietary drugs, licensing agreements, and potential partnerships with larger pharmaceutical companies.
At a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Woburn, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 60.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Biotechnology, Gastroenterology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Neurogastrx.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2021 | $60M | $240M | Vivo Capital · RTW Investments · Marshall Wace · Samsara BioCapital | — |
| SERIES AOther financing | Jan 2018 | $45M | $180M | OrbiMed · venBio Partners · 5AM Ventures | — |
Growth signals
Latest recorded traffic for Neurogastrx is 1.1K monthly website visits, up 32.5% over the last three months. Neurogastrx's team declined 57.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
OrbiMed
venBio Partners
5AM Ventures
Vivo Capital
RTW Investments
Marshall Wace
Samsara BioCapital
Other known investors1 additional known investor
Johns Hopkins University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neurogastrx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neurogastrx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.